Your shopping cart is currently empty

TDN345 is a antagonist of Ca2+, for the treatment of vascular and senile dementia including Alzheimer's disease.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,670 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $2,180 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $2,800 | 6-8 weeks | 6-8 weeks |
| Description | TDN345 is a antagonist of Ca2+, for the treatment of vascular and senile dementia including Alzheimer's disease. |
| In vitro | In the time-course study,TDN-345 treatment with 10 μM significantly increases the intracellular NGF content. TDN-345 induces NGF synthesis/secretion at the concentrations of 0.1 μM; statistically significant at 1 μM(ED50 of 0.88 μM)[1]. |
| In vivo | When administered orally twice TDN-345 (0.1-1.0 mg/kg, p.o.) dose-dependently decreases the mortality and ischemic neurological deficit score, 60 min before ischemia and 90 min after recirculation. Additionally, In SHRSP, TDN-345 decreases the mortality and recurrence of stroke [2]. |
| Molecular Weight | 468.58 |
| Formula | C28H34F2N2O2 |
| Cas No. | 134069-68-4 |
| Smiles | C=C1C2(OC(=O)N1C(C)(C)C)CCN(CCCC(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2 |
| Relative Density. | 1.18 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.